A rare cause of hydrops fetalis in two Gaucher disease type 2 patients with a novel mutation.


Journal

Metabolic brain disease
ISSN: 1573-7365
Titre abrégé: Metab Brain Dis
Pays: United States
ID NLM: 8610370

Informations de publication

Date de publication:
04 2022
Historique:
received: 17 11 2021
accepted: 22 02 2022
pubmed: 8 3 2022
medline: 29 4 2022
entrez: 7 3 2022
Statut: ppublish

Résumé

Gaucher disease type 2 is the most progressive and the rarest form of Gaucher disease, defined as the acute neuronopathic type. We presented two GD2 patients who died before three months of age due to severe septicemia, respiratory and liver failure. One was homozygous for a novel GBA variant c.590 T > A (p.197 K), and the second homozygous for the known GBA mutation c.1505G > A (p.R502H). Ichthyosis, hydrops fetalis, apnea, myoclonic seizures, and hepatosplenomegaly occurred in both patients, but hypertrophic cardiomyopathy was observed only in the second and unilateral cataract in the first patient. Due to the disease's early and rapid neurological progression, we did not administer ERT to our patients. It is strongly believed that early diagnosis is essential, and prenatal diagnosis makes genetic counselling possible for future pregnancies.

Identifiants

pubmed: 35254599
doi: 10.1007/s11011-022-00942-5
pii: 10.1007/s11011-022-00942-5
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1283-1287

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Akdag A, Oguz SS, Ezgu F, Erdeve O, Uras N, Dilmen U (2011) A newborn case with perinatal-lethal Gaucher disease due to R463H homozygosity complicated by C677T homozygosity in the MTHFR gene. J Pediatr Endocrinol Metab 24(5-6):381–383. https://doi.org/10.1515/jpem.2011.001
doi: 10.1515/jpem.2011.001 pubmed: 21823541
Alfonso P, Aznarez S, Giralt M, Pocovi M, Giraldo P, Spanish Gaucher's Disease, R (2007) Mutation analysis and genotype/phenotype relationships of Gaucher disease patients in Spain. J Hum Genet 52(5):391–396. https://doi.org/10.1007/s10038-007-0135-4
doi: 10.1007/s10038-007-0135-4 pubmed: 17427031
BenHamida E, Ayadi I, Ouertani I, Chammem M, Bezzine A, BenTmime R et al (2015) Perinatal-lethal Gaucher disease presenting as hydrops fetalis. Pan Afr Med J 21:110. https://doi.org/10.11604/pamj.2015.21.110.7052
doi: 10.11604/pamj.2015.21.110.7052 pubmed: 26327947 pmcid: 4546719
Bronstein S, Karpati M, Peleg L (2014) An update of Gaucher mutations distribution in the Ashkenazi Jewish population: prevalence and country of origin of the mutation R496H. Isr Med Assoc J 16(11):683–685 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25558695
pubmed: 25558695
Bulut FD, Kor D, Seker-Yilmaz B, Herguner O, Ceylaner S, Ozkinay F et al (2018) Four Gaucher disease type II patients with three novel mutations: a single Centre experience from Turkey. Metab Brain Dis 33(4):1223–1227. https://doi.org/10.1007/s11011-018-0236-0
doi: 10.1007/s11011-018-0236-0 pubmed: 29656334
Campbell PE, Harris CM, Harris CM, Sirimanna T, Vellodi A (2003) A model of neuronopathic Gaucher disease. J Inherit Metab Dis 26(7):629–639. https://doi.org/10.1023/b:boli.0000005619.14180.5c
doi: 10.1023/b:boli.0000005619.14180.5c pubmed: 14707511
Daykin EC, Ryan E, Sidransky E (2021) Diagnosing neuronopathic Gaucher disease: new considerations and challenges in assigning Gaucher phenotypes. Mol Genet Metab 132(2):49–58. https://doi.org/10.1016/j.ymgme.2021.01.002
doi: 10.1016/j.ymgme.2021.01.002 pubmed: 33483255 pmcid: 7884077
Eblan MJ, Goker-Alpan O, Sidransky E (2005) Perinatal lethal Gaucher disease: a distinct phenotype along the neuronopathic continuum. Fetal Pediatr Pathol 24(4-5):205–222. https://doi.org/10.1080/15227950500405296
doi: 10.1080/15227950500405296 pubmed: 16396828
Grace ME, Balwani M, Nazarenko I, Prakash-Cheng A, Desnick RJ (2007) Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations-implications for diagnosis and therapeutic monitoring. Hum Mutat 28(9):866–873. https://doi.org/10.1002/humu.20524
doi: 10.1002/humu.20524 pubmed: 17464953
Haverkaemper S, Marquardt T, Hausser I, Timme K, Kuehn T, Hertzberg C, Rossi R (2011) Congenital ichthyosis in severe type II Gaucher disease with a homozygous null mutation. Neonatology 100(2):194–197. https://doi.org/10.1159/000324116
doi: 10.1159/000324116 pubmed: 21455010
Inui K, Yanagihara K, Otani K, Suzuki Y, Akagi M, Nakayama M et al (2001) A new variant neuropathic type of Gaucher's disease characterized by hydrocephalus, corneal opacities, deformed toes, and fibrous thickening of spleen and liver capsules. J Pediatr 138(1):137–139. https://doi.org/10.1067/mpd.2001.109789
doi: 10.1067/mpd.2001.109789 pubmed: 11148530
Kooper AJ, Janssens PM, de Groot AN, Liebrand-van Sambeek ML, van den Berg CJ, Tan-Sindhunata GB, ..., Wevers RA (2006) Lysosomal storage diseases in non-immune hydrops fetalis pregnancies. Clin Chim Acta 371(1-2): 176–182. https://doi.org/10.1016/j.cca.2006.03.007
Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ et al (2000) Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 66(6):1777–1786. https://doi.org/10.1086/302925
doi: 10.1086/302925 pubmed: 10796875 pmcid: 1378059
Lui K, Commens C, Choong R, Jaworski R (1988) Collodion babies with Gaucher's disease. Arch Dis Child 63(7):854–856. https://doi.org/10.1136/adc.63.7.854
doi: 10.1136/adc.63.7.854 pubmed: 3415310 pmcid: 1779077
Migita M, Hamada H, Fujimura J, Watanabe A, Shimada T, Fukunaga Y (2003) Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy--unsuccessful treatment of the neurological abnormality in type 2 Gaucher disease. Eur J Pediatr 162(7-8):524–525. https://doi.org/10.1007/s00431-001-0859-7
doi: 10.1007/s00431-001-0859-7 pubmed: 12845529
Mignot C, Gelot A, Bessieres B, Daffos F, Voyer M, Menez F et al (2003) Perinatal-lethal Gaucher disease. Am J Med Genet A 120A(3):338–344. https://doi.org/10.1002/ajmg.a.20117
doi: 10.1002/ajmg.a.20117 pubmed: 12838552
Nagappa M, Bindu PS, Taly AB, Sinha S (2015) Oculomotor apraxia in Gaucher disease. Pediatr Neurol 52(4):468–469. https://doi.org/10.1016/j.pediatrneurol.2014.10.016
doi: 10.1016/j.pediatrneurol.2014.10.016 pubmed: 25687160
Pastores GM, Hughes DA (1993) Gaucher Disease. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A (eds) GeneReviews((R)), Seattle (WA)
Plakkal N, Soraisham AS, Jirapradittha J, Pinto-Rojas A (2011) Perinatal lethal Gaucher disease. Indian J Pediatr 78(1):106–108. https://doi.org/10.1007/s12098-010-0247-2
doi: 10.1007/s12098-010-0247-2 pubmed: 20924719
Roshan Lal T, Sidransky E (2017) The Spectrum of neurological manifestations associated with Gaucher disease. Diseases 5(1). https://doi.org/10.3390/diseases5010010
Roshan Lal T, Seehra GK, Steward AM, Poffenberger CN, Ryan E, Tayebi N et al (2020) The natural history of type 2 Gaucher disease in the 21st century: a retrospective study. Neurology 95(15):e2119–e2130. https://doi.org/10.1212/WNL.0000000000010605
doi: 10.1212/WNL.0000000000010605 pubmed: 32764102 pmcid: 7713752
Staretz-Chacham O, Lang TC, LaMarca ME, Krasnewich D, Sidransky E (2009) Lysosomal storage disorders in the newborn. Pediatrics 123(4):1191–1207. https://doi.org/10.1542/peds.2008-0635
doi: 10.1542/peds.2008-0635 pubmed: 19336380
Stone DL, Carey WF, Christodoulou J, Sillence D, Nelson P, Callahan M et al (2000a) Type 2 Gaucher disease: the collodion baby phenotype revisited. Arch Dis Child Fetal Neonatal Ed 82(2):F163–F166. https://doi.org/10.1136/fn.82.2.f163
doi: 10.1136/fn.82.2.f163 pubmed: 10685993 pmcid: 1721053
Stone DL, Tayebi N, Orvisky E, Stubblefield B, Madike V, Sidransky E (2000b) Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum Mutat 15(2):181–188. https://doi.org/10.1002/(SICI)1098-1004(200002)15:2<181::AIDHUMU7>3.0.CO;2-S
doi: 10.1002/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.0.CO;2-S pubmed: 10649495
Weiss K, Gonzalez A, Lopez G, Pedoeim L, Groden C, Sidransky E (2015) The clinical management of type 2 Gaucher disease. Mol Genet Metab 114(2):110–122. https://doi.org/10.1016/j.ymgme.2014.11.008
doi: 10.1016/j.ymgme.2014.11.008 pubmed: 25435509

Auteurs

Sebile Kılavuz (S)

Division of Pediatric Metabolism and Nutrition, Department of Pediatrics, Van Training and Research Hospital, University of Health Sciences, Van, Turkey. dr.skilavuz@gmail.com.
Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK. dr.skilavuz@gmail.com.

Murat Basaranoglu (M)

Division of Neonatology, Department of Pediatrics, University of Health Sciences, Van Training and Research Hospital, Van, Turkey.

Serdar Epcacan (S)

Division of Pediatric Cardiology Disease, Department of Pediatrics, University of Health Sciences, Van Training and Research Hospital, Van, Turkey.

Derya Bako (D)

Divisions of Pediatric Radiology, Department of Radiology, University of Health Sciences, Van Training and Research Hospital, Van, Turkey.

Arife Ozer (A)

Division of Pediatric Infectious Disease, Department of Pediatrics, University of Health Sciences, Van Training and Research Hospital, Van, Turkey.

Yasemin Nuran Donmez (YN)

Division of Pediatric Cardiology Disease, Department of Pediatrics, University of Health Sciences, Van Training and Research Hospital, Van, Turkey.

Emine Ipek Ceylan (EI)

Department of Medical Genetics, University of Health Sciences, Van Training and Research Hospital, Van, Turkey.

Ajlan Tukun (A)

Department of Medical Genetics, Duzen Laboratory, Ankara, Turkey.

Serdar Ceylaner (S)

Intergen Genetic Diagnosis and Research Center, Ankara, Turkey.
Department of Medical Genetics, Medical Faculty, Lokman Hekim University, Ankara, Turkey.

Hadi Geylani (H)

Division of Pediatric Hematology, Department of Pediatrics, University of Health Sciences, Van Training and Research Hospital, Van, Turkey.

Halise Neslihan Onenli Mungan (HNO)

Division of Pediatric Metabolism and Nutrition, Department of Pediatrics, Çukurova University Faculty of Medicine, Adana, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH